Key Points
- CEO Eric Dube sold 100,087 shares of Travere Therapeutics on Feb. 3 at an average price of $32.28 for about $3.23M, cutting his holding by ~18.8% to 432,886 shares; several other senior executives also sold large blocks the same day, creating a broad insider sell‑off.
- Shares trade around $32.8 with a 52‑week range of $12.91–$42.13 and a market cap of ~$2.94B; analysts have a consensus rating of "Moderate Buy" and an average price target of $38.86 (individual targets up to $48).
Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CAO Sandra Calvin sold 4,333 shares of the company's stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $32.12, for a total value of $139,175.96. Following the completion of the transaction, the chief accounting officer directly owned 49,080 shares in the company, valued at approximately $1,576,449.60. The trade was a 8.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Sandra Calvin also recently made the following trade(s):
- On Wednesday, December 24th, Sandra Calvin sold 7,402 shares of Travere Therapeutics stock. The shares were sold at an average price of $40.00, for a total value of $296,080.00.
Travere Therapeutics Stock Down 0.8%
Shares of Travere Therapeutics stock opened at $32.84 on Wednesday. The stock has a market capitalization of $2.94 billion, a P/E ratio of -30.98, a PEG ratio of 1.01 and a beta of 0.83. Travere Therapeutics, Inc. has a 12-month low of $12.91 and a 12-month high of $42.13. The stock has a 50 day moving average price of $34.11 and a two-hundred day moving average price of $27.76. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the company. Piper Sandler boosted their target price on Travere Therapeutics from $26.00 to $35.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 4th. Citigroup upped their target price on shares of Travere Therapeutics from $34.00 to $48.00 and gave the stock a "buy" rating in a research note on Friday, October 31st. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Travere Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, December 13th. Finally, Guggenheim restated a "buy" rating and issued a $49.00 price target on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $38.86.
Get Our Latest Stock Report on Travere Therapeutics
Travere Therapeutics News Roundup
Here are the key news stories impacting Travere Therapeutics this week:
- Negative Sentiment: Multiple senior insiders sold large blocks of shares on Feb 3, including CEO Eric M. Dube (100,087 shares, ~18.8% reduction in his position) and several executives (CFO, CAO and other officers) reducing holdings by ~5–10% each — a broad, same-day executive sell-off that can signal rotation or prompt investor concern about near-term insider confidence. CEO Form 4
- Negative Sentiment: A recent article questions Travere’s disclosure and risk narrative, flagging potential credibility concerns that could amplify selling or increase short-term volatility if investors seek more clarity from management. Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative?
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Emerald Advisers LLC increased its position in shares of Travere Therapeutics by 2.6% during the third quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company's stock valued at $51,308,000 after acquiring an additional 55,407 shares during the last quarter. Capital Fund Management S.A. bought a new position in Travere Therapeutics in the 2nd quarter worth approximately $1,501,000. Squarepoint Ops LLC boosted its stake in Travere Therapeutics by 98.7% in the 2nd quarter. Squarepoint Ops LLC now owns 479,394 shares of the company's stock worth $7,095,000 after purchasing an additional 238,070 shares during the period. Voya Investment Management LLC increased its holdings in Travere Therapeutics by 16.2% during the 3rd quarter. Voya Investment Management LLC now owns 194,854 shares of the company's stock worth $4,657,000 after acquiring an additional 27,133 shares during the period. Finally, Lisanti Capital Growth LLC purchased a new stake in shares of Travere Therapeutics in the 3rd quarter valued at about $3,095,000.
Travere Therapeutics Company Profile
(
Get Free Report)
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
